Skip to main content

Kling Douglas F's Form 4 filing

NewAmsterdam Pharma Co N.V. (NAMS) · filed Jul 17, 2025

Accession no.
0000950170-25-096665
Filed
Jul 17, 2025
Trade date
Jul 15-16, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.10M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kling Douglas FCIK 0001699022Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 15, 2025Ordinary SharesMOption exerciseAcquired+47,569$10.90+$518,502.191,569Direct
Jul 15, 2025Ordinary SharesSSaleDisposed−44,025$21.38−$941,254.547,544Direct
Jul 15, 2025Ordinary SharesSSaleDisposed−3,544$22.12−$78,393.2844,000Direct
Jul 16, 2025Ordinary SharesMOption exerciseAcquired+51,043$10.90+$556,368.795,043Direct
Jul 16, 2025Ordinary SharesSSaleDisposed−51,043$21.10−$1,077,007.344,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 15, 2025Ordinary SharesMOption exerciseDisposed−47,569$0.00$0213,745Direct
Jul 16, 2025Ordinary SharesMOption exerciseDisposed−51,043$0.00$0162,702Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)